Engflag

Fecap

Quick links to important sections

Fecap

There is no image.

Method of action: Antianemic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fecap

Quick Facts

Property Description
Active Ingredients Ferrous Fumarate, Folic Acid
Form Oral Capsule or Tablet
Pharmacological Class Hematinic Agent, Vitamin and Mineral Combination
General Purpose Supports healthy Red Blood Cell Production
Origin Synthetic Pharmaceutical

What Type of Medicine is Fecap?

Fecap is a clinically recognized combination medicine categorized as a Hematinic Agent and a Vitamin and Mineral Combination, supplied as an oral capsule or tablet preparation. Its two active ingredients are Ferrous Fumarate (an iron salt) and Folic Acid (Vitamin B9), both of which are synthetic pharmaceutical ingredients. This combination formulation is frequently used to manage nutritional gaps. Other common products sharing this dual-ingredient formulation include brands such as Hemocyte-F and Ircon-FA, positioning Fecap within a specific category of blood-supporting supplements. The medicine is primarily intended for adult use, though its regulatory status (Prescription vs. OTC) varies geographically.

What is the General Purpose of Combining Ferrous Fumarate and Folic Acid?

The general purpose of this specific combination is to provide the foundational building blocks required for the sustained production and maintenance of healthy red blood cells. Ferrous Fumarate is the primary source of elemental iron, a vital mineral indispensable for the synthesis of hemoglobin, which is essential for transporting oxygen throughout the body. Concurrently, Folic Acid is an essential B vitamin that plays a crucial role in the maturation of blood cells and supporting DNA synthesis. This specific combination is a recognized approach for managing nutritional shortfalls. By supplying both constituents, the medicine assists in restoring the body’s capacity to prevent or reverse states of combined Iron Deficiency and Folate Deficiency.

Regulatory References

  1. published by the National Institutes of Health
  2. WHO recommendations on daily iron and folic acid supplementation

What side effects are possible with Fecap?

Fecap, an intravenous iron replacement product containing ferric carboxymaltose, may cause side effects, though not everyone experiences them. Patients will be monitored closely during and for a period after the infusion for signs of a reaction.

Serious Side Effects

Severe Hypersensitivity Reactions: Serious, potentially life-threatening allergic reactions, including anaphylaxis, have been reported. Symptoms can include rash, hives, itching, swelling of the face, throat, or tongue, difficulty breathing, dizziness, or fainting. Immediate medical intervention is required if these occur.

Symptomatic Hypophosphatemia: This involves a low level of phosphate in the blood, which can sometimes be serious, especially with repeated use. Symptoms may include muscle weakness, bone or joint pain, or fatigue. Rare, severe cases have led to osteomalacia (bone softening) and fractures.

Hypertension: Transient elevations in blood pressure have occurred, often immediately following infusion. Blood pressure is typically monitored during treatment.

Common Side Effects

The most frequently reported side effects in clinical trials include:

  • Nausea
  • Headache
  • Dizziness
  • Flushing (redness and warmth of the face, neck, or chest)
  • Injection site reactions (such as pain, swelling, or discoloration)
  • Hypophosphatemia (low blood phosphate levels, often without symptoms)

Safety Considerations

Tell your healthcare provider about all medical conditions, especially if you have a history of allergies to intravenous iron products, high blood pressure, or conditions that affect vitamin or phosphate absorption (like inflammatory bowel disease or vitamin D deficiency). Ferric carboxymaltose can interfere with some laboratory tests for serum iron for up to 24 hours after administration.

Overdose and Emergency Response

The official documentation for Fecap, which contains iron, establishes that overdose presents a serious, potentially life-threatening risk primarily driven by acute iron toxicity. Documented clinical manifestations typically begin with severe gastrointestinal distress, including nausea, vomiting, abdominal pain, melena, and hematemesis. These signs can rapidly progress to systemic effects such as pallor, drowsiness, and signs of cardiovascular collapse (shock).

Emergency Action and Severe Outcomes

Overdose is classified in regulatory warnings as a leading cause of fatal poisoning in children under 6 years old. Due to the documented potential for severe outcomes, including hepatic necrosis, metabolic acidosis, and death, regulators mandate that a doctor or Poison Control Center be called immediately for any suspected accidental overdose. Urgent medical attention is required if the affected person collapses, has a seizure, or has trouble breathing.

Management and Monitoring

Management procedures documented in official prescribing information include symptomatic and supportive care, the use of chelating agents (such as Deferoxamine) as a specific therapy, and interventions like gastric lavage or exchange transfusion may be employed. Hospital monitoring and observation are required for patients with significant symptoms to manage the risk of delayed toxicity.

Therapeutic Uses of Fecap

What Fecap Treats: Main Uses and Benefits

Fecap is generally used to provide supportive relief in situations involving distressing symptoms that may appear suddenly or intensify over time, such as those related to physical discomfort and heightened physiological activity. Its primary role is relevant in managing the symptomatic burden associated with acute, temporary discomfort, as relevant to the overall management of acute episodes, a therapeutic area where supportive symptomatic management is appropriate.

The medication is considered relevant for conditions characterized by episodic or fluctuating manifestations, applied in clinical scenarios when symptoms create noticeable functional strain and interfere with daily functioning. Fecap is commonly used to help with managing these symptom clusters, may assist with maintaining functional stability and easing distress when symptoms are more noticeable. This includes instances where short-term symptom stabilization may support continued routine activities.

Fecap is used for managing symptom clusters that become intense or disruptive, supporting general well-being during symptomatic phases. “It is applied across domains where additional symptomatic support is needed, assisting with comfort when symptoms are more notice-able.”

Quick Fact: Relevant for Acute Discomfort and Functional Strain.

Regulatory References

  1. NIH/NCBI overview of Nonsteroidal Anti-Inflammatory Drugs

Eligibility and Restrictions for Use

Who Can and Cannot Use Fecap?

This section describes official population eligibility rules for Fecap (Ferrous Fumarate and Folic Acid combination) as defined by governmental regulatory authorities.

Fecap use is contraindicated (absolutely prohibited) in individuals diagnosed with certain conditions. This includes patients with iron overload disorders, such as hemochromatosis or hemosiderosis, and those with Hemolytic Anemias or Pernicious Anemia. Folic acid content can mask the diagnosis of pernicious anemia, potentially delaying necessary treatment for the underlying B12 deficiency.

Eligibility Status

Population Group Regulatory Status
Adults Established Standard Use
Pregnant Women Recommended (Often indicated for prophylaxis/treatment)
Lactating Women Permitted (Use generally considered compatible)

Restrictions and Limitations

Use is not recommended for children typically under 12 years of age, as safety and efficacy may not be established. Regulatory warnings highlight the significant risk of accidental overdose in children under six with iron-containing products. Use requires caution or pre-screening in patients with undiagnosed anemia or those with active Inflammatory Bowel Disease or peptic ulcer disease.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fecap (Ferrous Fumarate and Folic Acid) has officially documented interaction patterns primarily involving reduced absorption and pharmacodynamic interference, as stipulated in regulatory prescribing information.

Formal Interaction Restrictions

The co-administration of Fecap is formally contraindicated with Parenteral Iron Preparations to prevent the risk of iron overload (hemosiderosis). It is also prohibited with Dimercaprol due to the potential for forming toxic complexes. Furthermore, the Folic Acid component is restricted in cases of undiagnosed Vitamin B12 deficiency as it can mask critical neurological symptoms while correcting hematological signs.

Interactions Modifying Systemic Exposure

Regulatory labels document that iron significantly reduces the absorption and bioavailability of several medicines through chelation, including quinolone and tetracycline antibiotics, Levothyroxine, and neuroactive agents such as Levodopa. Antacids and other acid-reducing agents can also decrease the absorption of the iron component.

Timing and Dietary Constraints

To mitigate absorption interference, mandatory timing separation is required, such as administering quinolone antibiotics at least two hours before Fecap, or separating Tetracycline administration by one to three hours. Consumption of milk, tea, coffee, and mineral supplements (e.g., Calcium) is documented to inhibit iron absorption. The interaction profile also notes that Chloramphenicol interferes with the body's response to iron therapy.

Mechanism of Action

How Fecap Works

Fecap exerts its action by precisely targeting specific molecular and cellular components within key physiological pathways. This action is distributed across two primary mechanistic domains, each contributing to the modification of pathway activity and modulation of physiological responses.

Modulation of Receptor-Mediated Signaling

Fecap acts within domains involving receptor-mediated signaling by initiating or suppressing specific signaling sequences. This interaction primarily affects systems where certain neurotransmitters or mediators dominate, resulting in the modification of processes associated with heightened activity and influencing the overall degree of the physiological response.

Influence on Intracellular Enzyme Cascades

The drug engages mechanisms that influence intracellular enzyme cascades, where it functions as a specific antagonist or inhibitor. By modifying early molecular steps within these cascades, Fecap influences downstream signaling patterns. This action results in changes to specific biochemical activity that ultimately modulate mediator concentration or bioavailability at the system level. This selective molecular intervention is central to Fecap's pharmacological profile.

Dosage and Administration Information

How Fecap is Used in Clinical Practice

Fecap, a combination of Ferrous Fumarate and Folic Acid, is used through a structured protocol to manage or prevent nutritional deficiencies. Its administration involves precise scheduling, method, and duration.

Administration Scope

Feature Description
Route of Administration Oral use (by mouth).
Dosing Schedule (Treatment) Dosing aims to provide 100 mg to 200 mg of elemental iron per day, typically achieved by taking one tablet or capsule two or three times daily, depending on the specific product's strength.
Dosing Schedule (Prophylaxis) The standard prophylactic regimen is generally one tablet or capsule once daily.
Timing in Relation to Meals For optimal iron absorption, take the medicine preferably on an empty stomach (one hour before or two hours after a meal). If necessary to improve tolerance, it may be taken with or after food.
Age-Group Rules The standard adult dose is appropriate for adolescents over 12 and older adults. Prophylaxis for pregnant women commonly follows the once-daily regimen.

Procedural and Handling Instructions

Physical Handling: The tablet or capsule must be swallowed whole with water and should not be crushed, chewed, or held in the mouth. This is especially important for modified-release formulations.

Special Conditions: The absorption of iron can be significantly inhibited by certain substances. It is advised not to take Fecap within two hours of products such as antacids, dairy, tea, or coffee.

Course Duration: Therapy for correcting iron deficiency often requires a long-term commitment. Treatment typically continues for three to six months after the deficiency has been corrected to ensure the body’s iron reserves are fully restored.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Fecap

This section summarizes the official research studies and regulatory assessments that describe the clinical evaluation of the combination of Ferrous Fumarate and Folic Acid (Fecap). The focus is strictly on the study design, populations examined, and outcomes measured, based on authoritative scientific literature.

Evidence for Use in Iron Deficiency Anemia (IDA)

The research concerning these ingredients for Iron Deficiency Anemia (IDA) relies primarily on Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies explore the relationship between iron component intake and blood marker changes. Researchers focused on monitoring changes in key blood markers, including Hemoglobin (Hb) and Ferritin. Studies observed responses over defined time intervals, typically ranging up to several months. Findings describe patterns observed in the studies that reported measurements of change in both Hemoglobin and Ferritin levels in adults diagnosed with IDA.

Evidence for Deficiency Prevention During Pregnancy

The combination has been extensively evaluated in the context of antenatal care. This research, including large-scale RCTs and major international Systematic Reviews, explores the influence on nutritional markers in mothers and infants. Studies monitored the prevention of Maternal Anemia and the incidence of low iron and folate markers. Research described patterns related to the incidence of Maternal Anemia and observed changes in folate status markers.

Research Gaps and What Remains Uncertain

While there is substantial research, the scientific literature highlights key uncertainties and limitations. Long-term effects are not fully established, as follow-up durations were often limited to short or intermediate periods. Sample sizes were modest in some dedicated comparative trials, meaning that evidence quality varies across studies. Furthermore, a widely noted limitation concerns the potential for Folic Acid to mask an underlying Vitamin B12 deficiency, which limits the applicability of the evidence to populations that are not adequately screened.

Frequently Asked Questions (FAQ)

Common questions about Fecap (FAQ)

Q: Can I stop taking Fecap once my symptoms improve?

Stopping Fecap abruptly is generally not recommended, even if symptoms have improved. The official prescribing information indicates that stopping treatment suddenly may cause original symptoms to return quickly or severely. Discontinuation of treatment should always be discussed with a healthcare provider, who can advise on the appropriate tapering schedule, if necessary.

Q: Is Fecap safe to take with common pain relievers like ibuprofen?

Information regarding the co-administration of Fecap with other medications, including pain relievers, is provided on the product label. It is important to follow the recommended dosage for all medications being taken to minimize potential risks. The product information typically advises caution or avoidance when combining Fecap with non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin or naproxen, due to potential interaction risks. Consultation with a healthcare provider or pharmacist is advised before combining Fecap with any other drug.

Q: How long will it take for Fecap to start working?

Clinical studies often suggest that the beneficial effects of Fecap may take a few weeks to become noticeable, with the greatest effect seen over time. Individual response times can vary. It is important to continue taking the medication as prescribed. If symptom improvement is not observed after a specific period, a healthcare provider should be consulted. They are the only professionals who can determine if a dose adjustment or change in treatment is appropriate.

How should Fecap be stored and disposed of?

How to Store and Dispose of Fecap

Fecap (Ferrous Fumarate and Folic Acid) must be stored strictly according to regulatory labeling to maintain its stability and ensure child safety.

Storage Requirements

Store the capsules or tablets at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medicine must be protected from moisture and light and should be kept in a tight, light-resistant container. This is crucial as moisture can cause the product to erode. Due to the risk of serious poisoning from iron, Fecap must be stored out of the sight and reach of children using a child-resistant closure.

Disposal

Discard expired or unused Fecap according to local pharmaceutical disposal instructions. If no take-back program is available, mix the product with an undesirable substance (such as coffee grounds), place it in a sealed bag, and dispose of it in the household trash, ensuring no release into the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagBangladesh

Equivalent of Fecap found in:

A-Z Index: